← Leaderboards
Marina Y Konopleva
University Of Tx Md Anderson Can Ctr
$11,210,192
Attributed
$16,020,833
Total exposure
14
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2009–24$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$24,240,801 · 15
By mechanism
R01$11,345,725 · 5
P50$9,040,449 · 3
R21$3,854,627 · 7
Top collaborators
- Guangrong Zheng7 shared
- Daohong Zhou7 shared
- Stefano Tiziani5 shared
- Amit Verma5 shared
- David H Spencer4 shared
- Elizabeth J Shpall3 shared
- John S Welch3 shared
- Michael W Andreeff2 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Christopher Chad Quarles$12,985,497
- Cassian Yee$17,221,393
- Maria Pia Morelli$1,662,703
Others in their field
Top investigators on “Leukemia”
- Richard K. Wilson · Washington University$209,620,938
- David Heimbrook · Leidos Biomedical Research, Inc.$168,419,678
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,967,203
- Peter C Adamson · National Childhood Cancer Foundation$143,910,899
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- Richard L Schilsky · University Of Chicago$129,102,207
Research focus
LeukemiaClinical TrialsRelapseBaseCellsIn VivoDesignBone MarrowMalignant NeoplasmsPharmaceutical PreparationsChemotherapyAcute Myelocytic LeukemiaIn VitroRefractoryResistanceResponseInhibitor/AntagonistToxic EffectMolecularApoptosisDoseSuccessLeukemic CellHematologic Neoplasms
Grant awards (57)
Inhibition of Bcl-xL by Targeted Degradation$480,430
R01 · FY2024 · CA
Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen$251,829
R01 · FY2024 · CA · contact PI
Targeting mitochondrial complex I in acute lymphoblastic leukemia$235,436
R01 · FY2024 · CA · contact PI
Inhibition of Bcl-xL by Targeted Degradation$495,601
R01 · FY2023 · CA
Targeting mitochondrial complex I in acute lymphoblastic leukemia$469,082
R01 · FY2023 · CA · contact PI
Defining the novel cancer testis antigen HSPA1L as immunotherapeutic target in AML$185,552
R21 · FY2023 · CA · contact PI
Administrative Core$177,359
P50 · FY2023 · CA · contact PI
Inhibition of Bcl-xL by Targeted Degradation$72,810
R01 · FY2023 · CA
Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen$45,505
R01 · FY2023 · CA · contact PI
SPORE University of Texas M. D. Anderson Cancer Center-Leukemia$1,689,836
P50 · FY2022 · CA · contact PI
Inhibition of Bcl-xL by Targeted Degradation$495,601
R01 · FY2022 · CA
Targeting mitochondrial complex I in acute lymphoblastic leukemia$287,375
R01 · FY2022 · CA · contact PI
Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen$270,880
R01 · FY2022 · CA · contact PI
Defining the novel cancer testis antigen HSPA1L as immunotherapeutic target in AML$227,205
R21 · FY2022 · CA · contact PI
Administrative Core$132,288
P50 · FY2022 · CA · contact PI
Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen$95,960
R01 · FY2022 · CA · contact PI
Targeting mitochondrial complex I in acute lymphoblastic leukemia$70,044
R01 · FY2022 · CA · contact PI
Career Enhancement Program$69,629
P50 · FY2022 · CA · contact PI
Chaperone-Mediated Protein Degradation of Bcl-xL and Bcl-2$46,984
R01 · FY2022 · CA
SPORE University of Texas M. D. Anderson Cancer Center-Leukemia$1,689,836
P50 · FY2021 · CA · contact PI
Targeting mitochondrial complex I in acute lymphoblastic leukemia$618,721
R01 · FY2021 · CA · contact PI
Inhibition of Bcl-xL by Targeted Degradation$505,715
R01 · FY2021 · CA
Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen$374,788
R01 · FY2021 · CA · contact PI
Administrative Core$132,288
P50 · FY2021 · CA · contact PI
Career Enhancement Program$69,630
P50 · FY2021 · CA · contact PI
SPORE University of Texas M. D. Anderson Cancer Center-Leukemia$1,738,656
P50 · FY2020 · CA · contact PI
Targeting mitochondrial complex I in acute lymphoblastic leukemia$625,201
R01 · FY2020 · CA · contact PI
Inhibition of Bcl-xL by Targeted Degradation$518,840
R01 · FY2020 · CA
Therapeutic targeting of glutamine metabolism in MDS$481,538
R01 · FY2020 · CA · contact PI
Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen$370,892
R01 · FY2020 · CA · contact PI
Administrative Core$143,319
P50 · FY2020 · CA · contact PI
Career Enhancement Program$95,968
P50 · FY2020 · CA · contact PI
SPORE University of Texas M. D. Anderson Cancer Center-Leukemia$1,708,776
P50 · FY2019 · CA · contact PI
Targeting mitochondrial complex I in acute lymphoblastic leukemia$587,548
R01 · FY2019 · CA · contact PI
Therapeutic targeting of glutamine metabolism in MDS$467,092
R01 · FY2019 · CA · contact PI
Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen$380,060
R01 · FY2019 · CA · contact PI
SPORE University of Texas M. D. Anderson Cancer Center-Leukemia$1,392,864
P50 · FY2018 · CA · contact PI
Therapeutic targeting of glutamine metabolism in MDS$496,810
R01 · FY2018 · CA · contact PI
Therapeutic targeting of glutamine metabolism in MDS$474,750
R01 · FY2017 · CA · contact PI
Therapeutic targeting of glutamine metabolism in MDS$506,879
R01 · FY2016 · CA · contact PI
Combination strategies to enhance therapy for Ph-like B-ALL$201,951
R21 · FY2016 · HD
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia$326,854
R01 · FY2015 · CA · contact PI
Combination strategies to enhance therapy for Ph-like B-ALL$256,714
R21 · FY2015 · HD
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia$317,049
R01 · FY2014 · CA · contact PI
Hypoxia-Selective Kinase Inhibitors for Leukemia Therapy$176,733
R21 · FY2014 · CA · contact PI
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia$307,243
R01 · FY2013 · CA · contact PI
Hypoxia-Selective Kinase Inhibitors for Leukemia Therapy$157,336
R21 · FY2013 · CA · contact PI
Targeting AKT signaling in AML$342,790
R21 · FY2012 · CA · contact PI
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia$326,854
R01 · FY2012 · CA · contact PI
Targeting AKT signaling in AML$357,290
R21 · FY2011 · CA · contact PI
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia$341,354
R01 · FY2011 · CA · contact PI
Combined inhibition of CXCR4 and FLT3-ITD signaling in acute myeloid leukemia$312,240
R21 · FY2011 · CA
Targeting hypoxic bone marrow microenvironment in Acute Myeloid Leukemia (AML)$302,829
R21 · FY2011 · CA · contact PI
Targeting the leukemia microenvironment by CXCR4 inhibition in stem cell transpla$338,800
R21 · FY2010 · CA · contact PI
Combined inhibition of CXCR4 and FLT3-ITD signaling in acute myeloid leukemia$336,397
R21 · FY2010 · CA
Targeting hypoxic bone marrow microenvironment in Acute Myeloid Leukemia (AML)$319,990
R21 · FY2010 · CA · contact PI
Targeting the leukemia microenvironment by CXCR4 inhibition in stem cell transpla$338,800
R21 · FY2009 · CA · contact PI